A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

ABSTRACT: The goal of this phase 1/2a sporozoite challenge trial (NCT01883609) was to evaluate novel malaria vaccination regimens of the GSK pre-erythrocytic RTS,S/AS01B vaccine alone and concomitantly same-site administered with the viral vectors ChAd63 & MVA encoding the liver stage antigen construct ME-TRAP. Four vaccine groups were studied and received three vaccinations at a monthly interval. All subjects then underwent controlled human malaria infection (CHMI) 11 weeks after first vaccine administration.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103862 | GEO | 2020/09/01

REPOSITORIES: GEO